pI: 6.5893 |
Length (AA): 360 |
MW (Da): 39418 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_145063)
Species | Accession | Gene Product |
---|---|---|
Leishmania braziliensis | LbrM.21.0180 | protein kinase, putative,serine/threonine protein kinase, putative |
Leishmania braziliensis | LbrM.21.0190 | protein kinase, putative,serine/threonine protein kinase, putative |
Leishmania donovani | LdBPK_210190.1 | serine/threonine protein kinase, putative |
Leishmania infantum | LinJ.21.0190 | protein kinase, putative,serine/threonine protein kinase, putative |
Leishmania major | LmjF.21.0130 | protein kinase, putative,serine/threonine protein kinase, putative |
Leishmania mexicana | LmxM.21.0130 | protein kinase, putative,serine/threonine protein kinase, putative |
Trypanosoma brucei gambiense | Tbg972.10.2310 | protein kinase, putative,serine/threonine protein kinase, putative |
Trypanosoma brucei | Tb11.v5.0556 | protein kinase, putative |
Trypanosoma brucei | Tb927.10.1910 | STE/STE11 serine/threonine-protein kinase, putative |
Trypanosoma congolense | TcIL3000_10_1620 | serine/threonine protein kinase, putative |
Trypanosoma cruzi | TcCLB.506493.70 | STE/STE11 serine/threonine-protein kinase, putative |
Trypanosoma cruzi | TcCLB.510121.150 | STE/STE11 serine/threonine-protein kinase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.10.1910 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.1910 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.1910 | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb927.10.1910 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Rattus norvegicus | Mitogen-activated protein kinase 1 | 358 aa | 23.3% | 288 aa | Compounds | References |
Rattus norvegicus | Cell division protein kinase 5 | 292 aa | 24.8% | 286 aa | Compounds | References |
Rattus norvegicus | Jak1 protein | 210 aa | 27.3% | 209 aa | Compounds | References |
Rattus norvegicus | Serine/threonine-protein kinase pim-3 | 326 aa | 25.6% | 266 aa | Compounds | References |
Plasmodium falciparum (isolate 3D7) | Cell division control protein 2 homolog | 288 aa | 27.8% | 284 aa | Compounds | References |
Homo sapiens | Cyclin-dependent kinase 1/cyclin B1 | 297 aa | 27.6% | 297 aa | Compounds | References |